Stay updated on Switching to Cabotegravir and Rilpivirine: Clinical Trial

Sign up to get notified when there's something new on the Switching to Cabotegravir and Rilpivirine: Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Switching to Cabotegravir and Rilpivirine: Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    The page now displays the clinical trial record, including study details, results measures, eligibility criteria, locations, and supporting documents, rather than a 403 error page.
    Difference
    100%
    Check dated 2026-11-08T13:55:22.000Z thumbnail image
  2. Check
    11 days ago
    Change Detected
    Summary
    The footer revision changes from v3.7.2 to v3.8.0 while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-01T15:13:34.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    A site-wide banner announces that NIH is transitioning to the term “Super Intelligence” in place of “Artificial Intelligence” and links to updates and FAQs.
    Difference
    1%
    Check dated 2026-10-25T14:07:49.000Z thumbnail image
  4. Check
    25 days ago
    Change Detected
    Summary
    The footer revision identifier changes from v3.7.1 to v3.7.2 on the ClinicalTrials.gov error page.
    Difference
    0.2%
    Check dated 2026-10-18T14:34:43.000Z thumbnail image
  5. Check
    32 days ago
    Change Detected
    Summary
    The footer's site revision identifier updates from v3.7.0 to v3.7.1. The page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-11T15:17:22.000Z thumbnail image
  6. Check
    53 days ago
    Change Detected
    Summary
    403 Forbidden error header now appears on the page, with a Home link and a Revision: v3.7.0 notice, replacing the previous study content and signaling that the page is inaccessible.
    Difference
    21%
    Check dated 2026-09-20T20:16:33.000Z thumbnail image

Stay in the know with updates to Switching to Cabotegravir and Rilpivirine: Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Switching to Cabotegravir and Rilpivirine: Clinical Trial page.